Symphogen raises 100 million euros and buys development time for cancer portfolio
This article was originally published in Scrip
Executive Summary
Symphogen has raised 100 million euros(131 million dollars), the largest ever financing for a private European biotech company, buying it time to complete several Phase IIa oncology trials before any future return to private investors or the public market for more funds. The Danish company is developing antibody and antibody combination therapeutics (monoclonals, monoclonal mixtures and polyclonals) to treat cancer, infectious and autoimmune diseases.